The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review

Journal of the American Society of Nephrology

Volumn 25, Issue 9, 2014, Pages 1897-1907

  Vanholder, Raymond ^a   Schepers, Eva ^a   Pletinck, Anneleen ^a   Nagler, Evi V ^a   Glorieux, Griet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; INDICAN; P CRESYL SULFATE; SULFATE; UNCLASSIFIED DRUG; UREMIC TOXIN; 4-CRESOL SULFATE; CRESOL; PROTEIN BINDING; TOXIN; UREMIA MIDDLE MOLECULE TOXINS;

BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; DETERIORATION; DOSE RESPONSE; HUMAN; IN VITRO STUDY; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UREMIA; ANIMAL; BIOLOGICAL MODEL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; KIDNEY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; CRESOLS; DISEASE MODELS, ANIMAL; HUMANS; INDICAN; KIDNEY; MODELS, BIOLOGICAL; PROTEIN BINDING; RENAL INSUFFICIENCY, CHRONIC; SULFURIC ACID ESTERS; TOXINS, BIOLOGICAL; UREMIA;

EID: 84921684023     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013101062     Document Type: Review

References (84)

1. Meyer TW, Hostetter TH: Uremia. N Engl J Med 357: 1316-1325, 2007
2. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J; European Uremic Toxin Work Group: A bench to bedside view of uremic toxins. J Am Soc Nephrol 19: 863-870, 2008
3. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? Pediatr Nephrol 23: 1211-1221, 2008
4. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943, 2003
5. Vanholder R, De Smet R, Lameire N: Proteinbound uremic solutes: The forgotten toxins. Kidney Int Suppl 78[Suppl 78]: S266-S270, 2001
6. Vanholder R, Schepers E, Pletinck A, Neirynck N, Glorieux G: An update on protein-bound uremic retention solutes. J Ren Nutr 22: 90-94, 2012
7. Glorieux G, Vanholder R: New uremic toxins -which solutes should be removed? Contrib Nephrol 168: 117-128, 2011
8. Neirynck N, Glorieux G, Schepers E, Pletinck A, Dhondt A, Vanholder R: Review of proteinbound toxins, possibility for blood purification therapy. Blood Purif 35[Suppl 1]: 45-50, 2013
9. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G: An update on uremic toxins. Int Urol Nephrol 45: 139-150, 2013
10. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P: p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 5: 1182-1189, 2010
11. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, Vanholder R: Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 49: 470-478, 2003
12. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P: Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73: 1174-1180, 2008
13. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uraemic Toxin Work Group (EUTox): Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25: 1183-1191, 2010
14. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH: Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 25: 3693-3700, 2010
15. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, Yeh LR, Chen HJ, Lee YJ, Houng JY: Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 211: 579-583, 2010
16. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, Hsu CC, Lu YC, Lee YJ, Houng JY: Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. JNephrol26:111-118,2013
17. Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, Wu MS: Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients-a prospective cohort study. NephrolDialTransplant27: 1169-1175, 2012
18. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS: p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 26: 938-947, 2011
19. Chiu CA, Lu LF, Yu TH, Hung WC, Chung FM, Tsai IT, Yang CY, Hsu CC, Lu YC, Wang CP, Lee YJ: Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud 7: 275-284, 2010
20. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23: 1258-1270, 2012
21. Hammarlund-Udenaes M: Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106: 215-220, 2010
22. Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH: Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol 99: 133-140, 2006
23. Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J: Introduction to drug pharmacokinetics in the critically ill patient. Chest 141: 1327-1336, 2012
24. Viaene L, Annaert P, de Loor H, Poesen R, Evenepoel P, Meijers B: Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. Biopharm Drug Dispos 34: 165-175, 2013
25. Sirich T, Meyer TW: Indoxyl sulfate: Long suspected but not yet proven guilty. Clin J Am Soc Nephrol 6: 3-4, 2011
26. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65: 442-451, 2004
27. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5: 1302-1308, 2007
28. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, Brunet P, Dignat-George F: Elevation of circulating endothelial microparticles in patients with chronic renal failure. JThrombHaemost4: 566-573, 2006
29. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T: Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 403: 1841-1850, 2012
30. Ito S, Osaka M, Higuchi Y, Nishijima F, Ishii H, Yoshida M: Indoxyl sulfate induces leukocyteendothelial interactions through up-regulation of E-selectin. JBiolChem285: 38869-38875, 2010
31. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R: P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22: 592-596, 2007
32. Tsujimoto M, Higuchi K, Shima D, Yokota H, Furukubo T, Izumi S, Yamakawa T, Otagiri M, Hirata S, Takara K, Nishiguchi K: Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro. J Pharm Pharmacol 62: 133-138, 2010
33. Yu M, Kim YJ, Kang DH: Indoxyl sulfateinduced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 6: 30-39, 2011
34. Sun CY, Hsu HH, Wu MS: p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant 28: 70-78, 2013
35. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H: Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 31: 1771-1779, 2010
36. Sun CY, Chang SC, Wu MS: Uremic toxins inducekidneyfibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE 7: e34026, 2012
37. Shimizu H, Bolati D, Higashiyama Y, Nishijima F, Shimizu K, Niwa T: Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NFκB, p53, ERK, and JNK in proximal tubular cells. Life Sci 90: 525-530, 2012
38. Bolati D, Shimizu H, Higashiyama Y, Nishijima F, Niwa T: Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am J Nephrol 34: 318-323, 2011
39. Sun CY, Chang SC, Wu MS: Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 81: 640-650, 2012
40. Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T: Indoxyl sulphate promotes aortic calcification with expression of osteoblastspecific proteins in hypertensive rats. Nephrol Dial Transplant 23: 1892-1901, 2008
41. Adijiang A, Higuchi Y, Nishijima F, Shimizu H, Niwa T: Indoxyl sulfate, a uremic toxin, promotes cell senescence in aorta of hypertensive rats. Biochem Biophys Res Commun 399:637-641, 2010
42. Shimizu H, Saito S, Higashiyama Y, Nishijima F, Niwa T: CREB, NF-κB, and NADPH oxidase coordinately upregulate indoxyl sulfate-induced angiotensinogen expression in proximal tubular cells. Am J Physiol Cell Physiol 304: C685-C692, 2013
43. shimizu h, yisireyili m, nishijima f, niwa t: indoxyl sulfate enhances p53-tgf-β1-smad3 pathway in proximal tubular cells. am jnephrol37: 97-103, 2013
44. Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z, Glorieux G, Vanholder R, Dugenet Y, Soula HA, Fouque D, Soulage CO: p-Cresyl sulfate promotes insulin resistance associated with CKD. JAmSocNephrol24: 88-99, 2013
45. Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, Noguchi T, Kadowaki D, Ishima Y, Kotani S, Nakajima M, Kataoka K, Kim-Mitsuyama S, Tanaka M, Fukagawa M, Otagiri M, Maruyama T: p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 83: 582-592, 2013
46. Chitalia VC, Shivanna S, Martorell J, Balcells M, Bosch I, Kolandaivelu K, Edelman ER: Uremic serum and solutes increase postvascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation 127: 365-376, 2013
47. Shimizu H, Yisireyili M, Higashiyama Y, Nishijima F, Niwa T: Indoxyl sulfate upregulates renal expression of ICAM-1 via production of ROS and activation of NF-κB and p53 in proximal tubular cells. Life Sci 92: 143-148, 2013
48. Tsujimoto M, Hatozaki D, Shima D, Yokota H, Furukubo T, Izumi S, Yamakawa T, Minegaki T, Nishiguchi K: Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin. Ther Apher Dial 16: 580-587, 2012
49. Yisireyili M, Shimizu H, Saito S, Enomoto A, Nishijima F, Niwa T: Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci 92: 1180-1185, 2013
50. Bolati D, Shimizu H, Yisireyili M, Nishijima F, Niwa T: Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-κB. BMC Nephrol 14: 56, 2013
51. YamamotoH,TsuruokaS,IokaT,AndoH,Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E: Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 69: 1780-1785, 2006
52. Odamaki M, Kato A, Kumagai H, Hishida A: Counter-regulatory effects of procalcitonin and indoxyl sulphate on net albumin secretion by cultured rat hepatocytes. Nephrol Dial Transplant 19: 797-804, 2004
53. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S: Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 47: 510-517, 1995
54. Zhu JZ, Zhang J, Yang K, Du R, Jing YJ, Lu L, Zhang RY: P-cresol, but not p-cresylsulphate, disrupts endothelial progenitor cell function in vitro. Nephrol Dial Transplant 27: 4323-4330, 2012
55. Viaene L, Evenepoel P, Meijers B, Vanderschueren D, Overbergh L, Mathieu C: Uremia suppresses immune signal-induced CYP27B1 expression in human monocytes. Am J Nephrol 36: 497-508, 2012
56. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P: The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54: 891-901, 2009
57. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048-1056, 2005
58. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375: 2073-2081, 2010
59. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R: Behavior of nonprotein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40: 339-347, 2002
60. Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, Van Landschoot M, Waterloos MA, Vanholder R: Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant 26: 2624-2630, 2011
61. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, Ledebo I, Vanholder R: Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective trial. Nephrol Dial Transplant 24: 562-570, 2009
62. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS; FHN Trial Group: In-center hemodialysis six times per week versus three times per week. N Engl J Med 363: 2287-2300, 2010
63. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. JAmSoc Nephrol 24: 487-497, 2013
64. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878: 2997-3002, 2010
65. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group: Effect of a carbonaceous oral adsorbent on the progression of CKD: A multicenter, randomized, controlled trial. Am J Kidney Dis 54: 459-467, 2009
66. Konishi K, Nakano S, Tsuda S, Nakagawa A, Kigoshi T, Koya D: AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 81: 310-315, 2008 67. 2013. Available at: http://www.medpagetoday.com/MeetingCoverage/ASN/35737. Accessed April 18, 2014
67. Winchester JF, Hostetter TH, Meyer TW: p-Cresol sulfate: Further understanding of its cardiovascular disease potential in CKD. Am JKidneyDis54: 792-794, 2009
68. Dobre M, Meyer TW, Hostetter TH: Searching for uremic toxins. Clin J Am Soc Nephrol 8: 322-327, 2013
69. Eden J, Levit L, Berg A, Morton S, editors: Finding What Works in Health Care: Standards for Systematic Reviews. Washington, D.C., The National Academies Press, 2011. Available at: http://www.nap.edu/openbook.php?record-id=13059. Accessed April 18, 2014
70. Sirich TL, Luo FJ, Plummer NS, Hostetter TH, Meyer TW: Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 27: 1574-1579, 2012
71. Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 114: S12-S19, 2009
72. Schepers E, Glorieux G, Vanholder R: The gut: The forgotten organ in uremia? Blood Purif 29: 130-136, 2010
73. Meijers BK, Weber V, Bammens B, Dehaen W, Verbeke K, Falkenhagen D, Evenepoel P: Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 32: 214-219, 2008
74. Eloot S, Van Biesen W, Glorieux G, Neirynck N, Dhondt A, Vanholder R: Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? PLoS ONE 8: e76838, 2013
75. Vanholder R, Glorieux G, De Smet R, Lameire N; European Uremic Toxin Work Group: New insights in uremic toxins. Kidney Int Suppl 84: S6-S10, 2003
76. Meert N, Schepers E, Glorieux G, Van Landschoot M, Goeman JL, Waterloos MA, Dhondt A, Van der Eycken J, Vanholder R: Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: Clinical data and pathophysiological implications. Nephrol Dial Transplant 27: 2388-2396, 2012
77. Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E, Massy Z, Evenepoel P: Warning: The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 26: 1464-1467, 2011
78. Gondouin B, Cerini C, Dou L, Sallee M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, Arnaud L, Vanholder R, Brunet P, Dignat-George F, Burtey S: Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 84: 733-744, 2013
79. Mutsaers HA, Wilmer MJ, Reijnders D, Jansen J, van den Broek PH, Forkink M, Schepers E, Glorieux G, Vanholder R, van den Heuvel LP, Hoenderop JG, Masereeuw R: Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta 1832: 142-150, 2013
80. van der Wal WM, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT, Korevaar JC, Geskus RB; Netherlands Cooperative Study on the Adequacy of Dialysis Study Group (NECOSAD): Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 26: 2978-2983, 2011
81. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 1551-1558, 2009
82. Szasz T, Thakali K, Fink GD, Watts SW: A comparison of arteries and veins in oxidative stress: Producers, destroyers, function, and disease. Exp Biol Med (Maywood) 232: 27-37, 2007
83. Mateo T, Naim Abu Nabah Y, Losada M, Estellés R, Company C, Bedrina B, Cerdá-Nicolás JM, Poole S, Jose PJ, Cortijo J, Morcillo EJ, Sanz MJ: A critical role for TNFalpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles. Blood 110: 1895-1902, 2007
84. Johnson AR: Human pulmonary endothelial cells in culture. Activities of cells from arteries and cells from veins. J Clin Invest 65: 841-850, 1980